141 related articles for article (PubMed ID: 35251213)
1. Safety Evaluation in Healthy Colombian Volunteers of P2Et Extract Obtained from
Duran MI; Ballesteros-Ramírez R; Tellez A; Torregrosa L; Olejua PA; Galvis S; Urueña C; Fiorentino S
Evid Based Complement Alternat Med; 2022; 2022():7943001. PubMed ID: 35251213
[TBL] [Abstract][Full Text] [Related]
2. Genotoxicity and mutagenicity assessment of a standardized extract (P2Et) obtained from
Ballesteros-Ramírez R; Durán MI; Fiorentino S
Toxicol Rep; 2021; 8():258-263. PubMed ID: 33552924
[TBL] [Abstract][Full Text] [Related]
3. An Immunomodulatory Gallotanin-Rich Fraction From
Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
Front Immunol; 2020; 11():584959. PubMed ID: 33312174
[TBL] [Abstract][Full Text] [Related]
4. Standardized Extract from Caesalpinia spinosa is Cytotoxic Over Cancer Stem Cells and Enhance Anticancer Activity of Doxorubicin.
Sandoval TA; Urueña CP; Llano M; Gómez-Cadena A; Hernández JF; Sequeda LG; Loaiza AE; Barreto A; Li S; Fiorentino S
Am J Chin Med; 2016; 44(8):1693-1717. PubMed ID: 27852125
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of P2Et extract from Caesalpinia spinosa in breast cancer patients: study protocol for a randomized double blind phase II clinical trial (CS003-BC).
Ballesteros-Ramírez R; Pinilla P; Sanchéz J; Torregrosa L; Aschner P; Urueña C; Fiorentino S
BMC Complement Med Ther; 2023 Sep; 23(1):309. PubMed ID: 37670337
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Acute and Chronic Toxicity in
Ballesteros-Ramírez R; Lasso P; Urueña C; Saturno J; Fiorentino S
J Toxicol; 2024; 2024():3769933. PubMed ID: 38633362
[TBL] [Abstract][Full Text] [Related]
7. Encapsulated Phytomedicines against Cancer: Overcoming the "Valley of Death".
Brotons-Canto A; Urueña CP; Imbuluzqueta I; Luque-Michel E; Martinez-López AL; Ballesteros-Ramírez R; Rojas L; Fiorentino S
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111524
[TBL] [Abstract][Full Text] [Related]
8. Polyphenol-rich extract induces apoptosis with immunogenic markers in melanoma cells through the ER stress-associated kinase PERK.
Prieto K; Cao Y; Mohamed E; Trillo-Tinoco J; Sierra RA; Urueña C; Sandoval TA; Fiorentino S; Rodriguez PC; Barreto A
Cell Death Discov; 2019; 5():134. PubMed ID: 31531232
[TBL] [Abstract][Full Text] [Related]
9. Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et).
Urueña C; Ballesteros-Ramírez R; Gomez-Cadena A; Barreto A; Prieto K; Quijano S; Aschner P; Martínez C; Zapata-Cardona MI; El-Ahanidi H; Jandus C; Florez-Alvarez L; Rugeles MT; Zapata-Builes W; Garcia AA; Fiorentino S
Front Med (Lausanne); 2022; 9():991873. PubMed ID: 36160152
[TBL] [Abstract][Full Text] [Related]
10. The delay in cell death caused by the induction of autophagy by P2Et extract is essential for the generation of immunogenic signals in melanoma cells.
Prieto K; Lozano MP; Urueña C; Alméciga-Díaz CJ; Fiorentino S; Barreto A
Apoptosis; 2020 Dec; 25(11-12):875-888. PubMed ID: 33156457
[TBL] [Abstract][Full Text] [Related]
11. Plant extract from
Jiménez MC; Prieto K; Lasso P; Gutiérrez M; Rodriguez-Pardo V; Fiorentino S; Barreto A
Heliyon; 2023 Mar; 9(3):e14148. PubMed ID: 36923867
[TBL] [Abstract][Full Text] [Related]
12. Gallotannin-rich Caesalpinia spinosa fraction decreases the primary tumor and factors associated with poor prognosis in a murine breast cancer model.
Urueña C; Mancipe J; Hernandez J; Castañeda D; Pombo L; Gomez A; Asea A; Fiorentino S
BMC Complement Altern Med; 2013 Apr; 13():74. PubMed ID: 23552194
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth.
Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Barreto A; Romero P; Fiorentino S
Front Oncol; 2018; 8():356. PubMed ID: 30234017
[TBL] [Abstract][Full Text] [Related]
14. A gallotannin-rich fraction from Caesalpinia spinosa (Molina) Kuntze displays cytotoxic activity and raises sensitivity to doxorubicin in a leukemia cell line.
Castañeda DM; Pombo LM; Urueña CP; Hernandez JF; Fiorentino S
BMC Complement Altern Med; 2012 Apr; 12():38. PubMed ID: 22490328
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of chemotherapy and P2Et extract combination in ex-vivo derived tumor mammospheres from breast cancer patients.
Urueña C; Sandoval TA; Lasso P; Tawil M; Barreto A; Torregrosa L; Fiorentino S
Sci Rep; 2020 Nov; 10(1):19639. PubMed ID: 33184339
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional T Lymphocytes Generated After Therapy With an Antitumor Gallotanin-Rich Normalized Fraction Are Related to Primary Tumor Size Reduction in a Breast Cancer Model.
Urueña C; Gomez A; Sandoval T; Hernandez J; Li S; Barreto A; Fiorentino S
Integr Cancer Ther; 2015 Sep; 14(5):468-83. PubMed ID: 26220604
[TBL] [Abstract][Full Text] [Related]
17. Study of the safety of oral Triphala aqueous extract on healthy volunteers.
Phetkate P; Kummalue T; Rinthong PO; Kietinun S; Sriyakul K
J Integr Med; 2020 Jan; 18(1):35-40. PubMed ID: 31680053
[TBL] [Abstract][Full Text] [Related]
18. Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model.
Gomez-Cadena A; Urueña C; Prieto K; Martinez-Usatorre A; Donda A; Barreto A; Romero P; Fiorentino S
Cell Death Dis; 2016 Jun; 7(6):e2243. PubMed ID: 27253407
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
20. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
